January 1, 2024
Fortis Life Sciences is thrilled to recap a year of significant achievements and milestones in 2023. As a testament to our commitment to innovation and excellence, we are proud to highlight some of our key successes from the past year.
International Point of Care (IPOC): In July Fortis announced the acquisition of IPOC, which develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. IPOC’s recently expanded 36,000 sq. ft. facility is Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America.